Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDT-301 Phase 1 Dose-Escalation in Healthy Adults
NCT05132907Phase 1Completed
- Sponsor
- HDT Bio
- Start
- Jan 2022
- Primary completion
- Nov 2023
- Modality
- Nanoparticles, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HDT-301 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by HDT Bio. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 2 more. Started Jan 2022; status: completed.
02
Drugs
HDT-301
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05132907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132907.